Rare diseases
Investigational molecules
Locations
185 Rue Raymond Losserand, 75014 Paris, France
Groupe Hospitalier Universitaire Paris Psychiatrie Et Neuroscience in Paris, France specialises in clinical trials of conditions such as Non-small cell lung cancer, Non-small cell lung cancer metastatic, Ischaemic stroke, Non-small cell lung cancer stage IV, and other specialisations. This site conducts important research.
The Institut de Neuromodulation is conducting studies that explore innovative therapies for acute ischemic stroke, aiming to improve functional recovery and quality of life.
These efforts at Groupe Hospitalier Universitaire Paris Psychiatrie Et Neuroscience reflect a commitment to advancing neurocritical care.
Clinical research focuses on novel interventions for major depressive disorder and treatment‑resistant forms, seeking faster symptom relief.
The site’s multidisciplinary team integrates psychiatry and neuromodulation to enhance mental health outcomes.
Trials evaluate strategies to prevent secondary events after ischemic stroke and to optimize anticoagulation in patients with vascular pathology.
Research at Groupe Hospitalier Universitaire Paris Psychiatrie Et Neuroscience aims to reduce mortality and disability from vascular disorders.
Investigators are testing immunomodulatory approaches for myasthenia gravis and sickle cell disease, targeting disease progression and organ protection.
The institute leverages its expertise in neuromodulation to modulate immune pathways for better patient outcomes.
Oncologic studies address aggressive brain tumors such as diffuse intrinsic pontine glioma, testing targeted agents combined with radiotherapy.
Through collaborations, the site strives to bring precision medicine to patients with rare central nervous system cancers.
Clinical trials currently enrolling participants at this site.
Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease
FrancePhase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer
FranceStudy of evenamide as add-on treatment for patients with treatment-resistant schizophrenia not adequately controlled by current antipsychotic medications
FranceStudy of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it
FranceFranceA Study of Setidegrasib with Chemotherapy Drug Combination as First‑Line Treatment in Adults with KRAS G12D‑mutated Metastatic Pancreatic Cancer
FranceAdjuvant Datopotamab Deruxtecan with Drug Combination in Patients with High‑Risk Muscle‑Invasive Urothelial Carcinoma
FranceLong‑term Safety of Adagrasib with Drug Combination in Adults with Solid Tumors
FranceA Study of ABBV-706 to Assess Safety and Efficacy Compared with Standard Drug Combination in Adults with Relapsed or Refractory Small Cell Lung Cancer
FranceRinatabart Sesutecan plus bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy
FranceDocetaxel and Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Have a Deep PSA Response After Initial Apalutamide Treatment
FrancePumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%
FranceMove up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.
